Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open Label First In Human Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor GRC 54276 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Pembrolizumab or Anti-PD-L1 Atezolizumab in Subjects With Advanced Solid Tumors and Lymphomas.

NCT05878691 is registered in ClinicalTrials.gov with Glenmark Specialty S.A. as lead sponsor.

NCT NCT05878691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05878691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open Label First In Human Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor GRC 54276 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Pembrolizumab or Anti-PD-L1 Atezolizumab in Subjects With Advanced Solid Tumors and Lymphomas.
Lead sponsor
Glenmark Specialty S.A.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 28, 2022
Completion date
July 30, 2027
Enrollment
320 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, lymphoma